Skip to content
10-Q

Quarterly Report

Janux Therapeutics, Inc. JANX

0001193125-26-212146

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 60.98M sh
Shares Diluted Q1 2026 · Mar 31, 2026 62.67M sh
Shares Diluted Q1 2026 · Mar 31, 2025 61.79M sh
Capex Q1 2026 · Mar 31, 2026 $273K
Capex Q1 2026 · Mar 31, 2025 $371K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$12.34M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$17.02M
Short Term Investments Q1 2026 · Mar 31, 2026 $904.56M
Short Term Investments Q1 2026 · Dec 31, 2025 $914.23M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $51.83M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $52.33M
Stockholders Equity Q1 2026 · Mar 31, 2026 $941.54M
Stockholders Equity Q1 2026 · Dec 31, 2025 $956.82M
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.01B
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.02B
Current Liabilities Q1 2026 · Mar 31, 2026 $58.92M
Current Liabilities Q1 2026 · Dec 31, 2025 $25M
Total Liabilities Q1 2026 · Mar 31, 2026 $86.69M
Total Liabilities Q1 2026 · Dec 31, 2025 $44.74M
Current Assets Q1 2026 · Mar 31, 2026 $1B
Current Assets Q1 2026 · Dec 31, 2025 $975.89M
Total Assets Q1 2026 · Mar 31, 2026 $1.03B
Total Assets Q1 2026 · Dec 31, 2025 $1B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.39
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.38
Eps Basic Q1 2026 · Mar 31, 2026 −$0.39
Eps Basic Q1 2026 · Mar 31, 2025 −$0.38
Sga Expense Q1 2026 · Mar 31, 2026 $11.13M
Sga Expense Q1 2026 · Mar 31, 2025 $9.84M
Rd Expense Q1 2026 · Mar 31, 2026 $26.81M
Rd Expense Q1 2026 · Mar 31, 2025 $25.06M
Net Income Q1 2026 · Mar 31, 2026 −$24.36M
Net Income Q1 2026 · Mar 31, 2025 −$23.51M
Operating Income Q1 2026 · Mar 31, 2026 −$34.21M
Operating Income Q1 2026 · Mar 31, 2025 −$34.9M
Revenue Q1 2026 · Mar 31, 2026 $3.73M
Revenue Q1 2026 · Mar 31, 2025 $0